These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 7327451

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Effects of dihydroergotamine mesylate (DEM) on the cardiovascular and nervous systems (author's transl)].
    Fukawa K, Honda H, Kubota H, Hatanaka Y, Sawabe T.
    Nihon Yakurigaku Zasshi; 1982 Mar; 79(3):225-36. PubMed ID: 7084820
    [Abstract] [Full Text] [Related]

  • 3. Studies on 5-hydroxytryptamine receptors on isolated human femoral veins and arteries and the influence of dihydroergotamine.
    Glusa E, Markwardt F.
    Pharmacology; 1984 Mar; 29(6):336-42. PubMed ID: 6505006
    [Abstract] [Full Text] [Related]

  • 4. In vitro studies on the duration of action of dihydroergotamine.
    Müller-Schweinitzer E.
    Int J Clin Pharmacol Ther Toxicol; 1980 Mar; 18(2):88-91. PubMed ID: 7372380
    [Abstract] [Full Text] [Related]

  • 5. Heterogeneity of 5-HT receptor subtypes in isolated human femoral and saphenous veins.
    Glusa E, Müller-Schweinitzer E.
    Naunyn Schmiedebergs Arch Pharmacol; 1993 Feb; 347(2):133-6. PubMed ID: 8474533
    [Abstract] [Full Text] [Related]

  • 6. Actions of co-dergocrine mesylate and its components at vascular smooth muscle.
    Müller-Schweinitzer E.
    Naunyn Schmiedebergs Arch Pharmacol; 1982 Feb; 318(3):225-33. PubMed ID: 7063048
    [Abstract] [Full Text] [Related]

  • 7. Dual effect of dihydroergotamine and dihydroergotoxin in isolated human femoral veins and arteries.
    Glusa E, Markwardt F.
    Pharmacology; 1982 Feb; 24(5):287-93. PubMed ID: 6285391
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. On the pharmacology of venous smooth muscle from dog and man.
    Müller-Schweinitzer E.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1979 Feb; 106(5-6):690-704. PubMed ID: 94863
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Responsiveness of isolated canine cerebral and peripheral arteries to ergotamine.
    Müller-Schweinitzer E.
    Naunyn Schmiedebergs Arch Pharmacol; 1976 Feb; 292(2):113-8. PubMed ID: 940593
    [Abstract] [Full Text] [Related]

  • 12. Effects of S-dobutamine on venous blood return and organ nutrient blood flow.
    Pollock GD, Bowling N, Tuttle RR, Hayes JS.
    J Cardiovasc Pharmacol; 1992 Feb; 20(5):742-9. PubMed ID: 1280736
    [Abstract] [Full Text] [Related]

  • 13. [Vasoconstrictor effects on isolated vessel segments determined by pressure-volume measurements].
    Weiss A, Koth W, Beer M, Glusa E, Markwardt F.
    Biomed Biochim Acta; 1986 Feb; 45(10):1285-93. PubMed ID: 3566719
    [Abstract] [Full Text] [Related]

  • 14. The reversibility of canine vein-graft arterialization.
    Fann JI, Sokoloff MH, Sarris GE, Yun KL, Kosek JC, Miller DC.
    Circulation; 1990 Nov; 82(5 Suppl):IV9-18. PubMed ID: 2225440
    [Abstract] [Full Text] [Related]

  • 15. Alpha-1 and alpha-2 adrenoceptor: response coupling in canine saphenous and femoral veins.
    Flavahan NA, Vanhoutte PM.
    J Pharmacol Exp Ther; 1986 Jul; 238(1):131-8. PubMed ID: 3014111
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.